Skip to main content

Nanomedicine for target-specific imaging and treatment of atherosclerosis: development and initial clinical feasibility

Objective

NanoAthero aims to have demonstration of initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented and provided evidence of efficacy of carriers and ligands. Over 5 years, NanoAthero will integrate GMP production, the initiation of clinical investigations in high-risk patients, including the preparation of regulatory dossiers, risk and ethical assessments, and the evaluation of the performance of optimized diagnostic and therapeutic compounds. NanoAthero offers a unique opportunity for combining in-depth knowledge of nanocarrier bioengineering and production with state-of the art expertise in imaging and treatment of cardiovascular patients providing a full bench-to-bedside framework within one collaborative consortium of 16 partners from academia, a European association, SMEs and a large pharmaceutical company. NanoAthero gathers together leading chemists, engineers, pharmacists, biologists, toxicologists, clinicians, analysts, ethicists and key-opinion leaders in the field of cardiovascular medicine and early drug development.
In NanoAthero, the nanocarriers carrying compounds to visualize thrombus or vulnerable plaques, or to deliver therapeutic agents should be suitable for proof-of-concept in patients. Phase I clinical trials targeting pivotal pathways in atherothrombosis will be performed with nanosystems for diagnosis and treatment of carotid atheroma. NanoAthero aims to propose nanosystems for thrombus imaging, stroke treatment and plaque stabilization in high-risk patients. Molecular imaging and therapeutic treatments in NanoAthero are based on feasible approaches.

Field of science

  • /medical and health sciences/basic medicine/neurology/stroke
  • /medical and health sciences/medical biotechnology/nanomedicine
  • /medical and health sciences/clinical medicine/cardiology/cardiovascular diseases/arteriosclerosis

Call for proposal

FP7-NMP-2012-LARGE-6
See other projects for this call

Funding Scheme

CP-IP - Large-scale integrating project

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
Rue De Tolbiac 101
75654 Paris
France
Activity type
Research Organisations
EU contribution
€ 1 387 267
Administrative Contact
Dina Falkenreck (Ms.)

Participants (15)

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
France
EU contribution
€ 600 889
Address
3 Avenue Victoria
75000 Paris
Activity type
Research Organisations
Administrative Contact
Alix Pillot (Mrs.)
INSERM TRANSFERT SA
France
EU contribution
€ 719 161,65
Address
Rue Watt 7
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Catherine Clusel (Dr.)
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
EU contribution
€ 831 716,80
Address
Meibergdreef 15
1105AZ Amsterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Gulseren Yalvac (Ms.)
MEDIZINISCHE UNIVERSITAT GRAZ
Austria
EU contribution
€ 525 701,20
Address
Auenbruggerplatz 2
8036 Graz
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ingrid Reinprecht (Ms.)
SYDDANSK UNIVERSITET
Denmark
EU contribution
€ 200 400
Address
Campusvej 55
5230 Odense M
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Arne Bækdal Hansen (Mr.)
UNIVERSITATSKLINIKUM ERLANGEN
Germany
EU contribution
€ 1 049 443,60
Address
Maximiliansplatz 2
91054 Erlangen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Karin Heuchemer (Ms.)
UNIVERSITEIT TWENTE
Netherlands
EU contribution
€ 687 522,75
Address
Drienerlolaan 5
7522 NB Enschede
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Ferdinand Damhuis (Mr.)
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Germany
EU contribution
€ 203 000
Address
Hofgartenstrasse 8
80539 Munich
Activity type
Other
Administrative Contact
Nadine Stolz (Ms.)
COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
France
EU contribution
€ 1 285 035
Address
Rue Leblanc 25
75015 Paris 15
Activity type
Research Organisations
Administrative Contact
Antoine Dupont (Mr.)
EUROPAISCHE STIFTUNG FUR KLINISCHE NANOMEDIZIN
Switzerland
EU contribution
€ 231 711,60
Address
Alemannengasse 12
4016 Basel
Activity type
Other
Administrative Contact
Beat Löffler (Mr.)
WINZSOFT (ISRAEL) LTD
Israel
EU contribution
€ 288 700
Address
Beit Hillel 3
67017 Tel Aviv-jaffo
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Avner Levy (Mr.)
NANOPET PHARMA GMBH
Germany
EU contribution
€ 511 800
Address
Robert-koch-platz 4
10115 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Bianca Grunert (Ms.)
SEMMELWEIS EGYETEM
Hungary
EU contribution
€ 389 800
Address
Ulloi Utca 26
1085 Budapest
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Vilmos Ivády (Dr.)
BRACCO IMAGING SPA
Italy
EU contribution
€ 816 191
Address
Via Egidio Folli 50
20134 Milan
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Giusy Galgano (Dr.)
EDINETHICS LIMITED
United Kingdom
EU contribution
€ 105 008,40
Address
Dundonald Street 11 6
EH3 6RZ Edinburgh
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Donald Bruce (Dr.)